Optimal management of hepatorenal syndrome in patients with cirrhosis
Hepatorenal syndrome (HRS) is a functional renal failure that often occurs in patients with cirrhosis and ascites. HRS develops as a consequence of a severe reduction of effective circulating volume due to both an extreme splanchnic arterial vasodilatation and a reduction of cardiac output. There ar...
| Main Authors: | , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
Dove Medical Press
2010
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3846372/ |
| id |
pubmed-3846372 |
|---|---|
| recordtype |
oai_dc |
| spelling |
pubmed-38463722013-12-23 Optimal management of hepatorenal syndrome in patients with cirrhosis Angeli, Paolo Morando, Filippo Review Hepatorenal syndrome (HRS) is a functional renal failure that often occurs in patients with cirrhosis and ascites. HRS develops as a consequence of a severe reduction of effective circulating volume due to both an extreme splanchnic arterial vasodilatation and a reduction of cardiac output. There are 2 different types of HRS. Type 1 HRS, which is often precipitated by a bacterial infection, especially spontaneous bacterial peritonitis, is characterized by a rapidly progressive impairment of renal function. Despite its functional origin, the prognosis of type 1 HRS is very poor. Type 2 HRS is characterized by a stable or slowly progressive renal failure so that its main clinical consequence is not acute renal failure but refractory ascites and its impact on prognosis is less negative. New treatments (vasoconstrictors plus albumin, transjugular portosystemic shunt, and molecular adsorbent recirculating system), which were introduced in the past 10 years, are effective in improving renal function in patients with HRS. Among these treatments vasoconstrictors plus albumin can also improve survival in patients with type 1 HRS. Thus, this therapeutic approach has changed the management of this severe complication in patients with advanced cirrhosis. Dove Medical Press 2010-06-21 /pmc/articles/PMC3846372/ /pubmed/24367209 Text en © 2010 Angeli and Morando, publisher and licensee Dove Medical Press Ltd This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited. |
| repository_type |
Open Access Journal |
| institution_category |
Foreign Institution |
| institution |
US National Center for Biotechnology Information |
| building |
NCBI PubMed |
| collection |
Online Access |
| language |
English |
| format |
Online |
| author |
Angeli, Paolo Morando, Filippo |
| spellingShingle |
Angeli, Paolo Morando, Filippo Optimal management of hepatorenal syndrome in patients with cirrhosis |
| author_facet |
Angeli, Paolo Morando, Filippo |
| author_sort |
Angeli, Paolo |
| title |
Optimal management of hepatorenal syndrome in patients with cirrhosis |
| title_short |
Optimal management of hepatorenal syndrome in patients with cirrhosis |
| title_full |
Optimal management of hepatorenal syndrome in patients with cirrhosis |
| title_fullStr |
Optimal management of hepatorenal syndrome in patients with cirrhosis |
| title_full_unstemmed |
Optimal management of hepatorenal syndrome in patients with cirrhosis |
| title_sort |
optimal management of hepatorenal syndrome in patients with cirrhosis |
| description |
Hepatorenal syndrome (HRS) is a functional renal failure that often occurs in patients with cirrhosis and ascites. HRS develops as a consequence of a severe reduction of effective circulating volume due to both an extreme splanchnic arterial vasodilatation and a reduction of cardiac output. There are 2 different types of HRS. Type 1 HRS, which is often precipitated by a bacterial infection, especially spontaneous bacterial peritonitis, is characterized by a rapidly progressive impairment of renal function. Despite its functional origin, the prognosis of type 1 HRS is very poor. Type 2 HRS is characterized by a stable or slowly progressive renal failure so that its main clinical consequence is not acute renal failure but refractory ascites and its impact on prognosis is less negative. New treatments (vasoconstrictors plus albumin, transjugular portosystemic shunt, and molecular adsorbent recirculating system), which were introduced in the past 10 years, are effective in improving renal function in patients with HRS. Among these treatments vasoconstrictors plus albumin can also improve survival in patients with type 1 HRS. Thus, this therapeutic approach has changed the management of this severe complication in patients with advanced cirrhosis. |
| publisher |
Dove Medical Press |
| publishDate |
2010 |
| url |
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3846372/ |
| _version_ |
1612032552526151680 |